Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 4, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2014-05-16
DOI
10.3389/fonc.2014.00108
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting TOR dependence in cancer
- (2015) Oncotarget
- Targeting mTOR for the treatment of AML. New agents and new directions.
- (2015) Jessica K. Altman et al. Oncotarget
- Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers
- (2013) Ju-yeon Jeong et al. APOPTOSIS
- Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia
- (2013) L. Willems et al. BLOOD
- Mechanistic / mammalian target protein of rapamycin signaling in hematopoietic stem cells and leukemia
- (2013) Atsushi Hirao et al. CANCER SCIENCE
- Toward a NOTCH1/FBXW7/RAS/PTEN–Based Oncogenetic Risk Classification of Adult T-Cell Acute Lymphoblastic Leukemia: A Group for Research in Adult Acute Lymphoblastic Leukemia Study
- (2013) Amélie Trinquand et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of PI3K inhibitors: lessons learned from early clinical trials
- (2013) Jordi Rodon et al. Nature Reviews Clinical Oncology
- Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia
- (2012) S. K. Tasian et al. BLOOD
- Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project
- (2012) M. L. Loh et al. BLOOD
- Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia
- (2012) S. L. Maude et al. BLOOD
- Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia
- (2012) Kathryn G. Roberts et al. CANCER CELL
- The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
- (2012) Jinghui Zhang et al. NATURE
- Targeting the PI3K/AKT/mTOR Signaling Axis in Children with Hematologic Malignancies
- (2012) David Barrett et al. PEDIATRIC DRUGS
- Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group
- (2011) J. Zhang et al. BLOOD
- Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway
- (2011) A M Martelli et al. LEUKEMIA
- Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia
- (2011) Priscila P Zenatti et al. NATURE GENETICS
- Rapamycin passes the torch: a new generation of mTOR inhibitors
- (2011) Don Benjamin et al. NATURE REVIEWS DRUG DISCOVERY
- Target of Rapamycin Signaling in Leukemia and Lymphoma
- (2010) C. Vu et al. CLINICAL CANCER RESEARCH
- Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program
- (2010) P. J. Houghton et al. MOLECULAR CANCER THERAPEUTICS
- Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia
- (2009) R. Crazzolara et al. BLOOD
- High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia
- (2009) A. Gutierrez et al. BLOOD
- Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies
- (2009) David T. Teachey et al. BRITISH JOURNAL OF HAEMATOLOGY
- Dual Inhibition of Class IA Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin as a New Therapeutic Option for T-Cell Acute Lymphoblastic Leukemia
- (2009) F. Chiarini et al. CANCER RESEARCH
- Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody
- (2009) N. Chapuis et al. HAEMATOLOGICA
- mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia
- (2008) D. T. Teachey et al. BLOOD
- Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor
- (2008) Chikara Hirase et al. LEUKEMIA RESEARCH
- Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program
- (2007) Peter J. Houghton et al. PEDIATRIC BLOOD & CANCER
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started